Oncocyte Corporation (OCX) saw downtrend of -4.76% in the recent trading with $2.80 being its most recent. The current price level -35.48% lower than the highest price of $4.34 marked by the stock while trading over the past 52-weeks, whereas it is 22.54% higher than the lowest price of $2.29 the company dropped to over past 52-weeks. The latest news story on OCX appeared in (GuruFocus.com) under the title “OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and.”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Squeezing the time span to 30 day period shows us the stock is currently trading -14.11% below one month high and is +3.70% above of the lowest during that time. Looking into the simple moving average, Oncocyte Corporation (OCX)’s stock stands at a SMA-50 of $3.03 while that of 5-day is reading $2.90.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and OCX’s SMA-200 as of now is $2.95.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.33 for the stock.
Oncocyte Corporation Earnings – What Happened With OCX
Coming around sales and income figures on OCX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
OCX – Oncocyte Corporation Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 16.84 million. OCX does have institutional investors; and they hold 50.57% of the stock.
Oncocyte Corporation – Insider Activity and Holdings
As on 2024-06-30, AWM INVESTMENT COMPANY, INC. was the top most holder in Oncocyte Corporation (NASDAQ:OCX) with an ownership of 1.1 million shares of the company or 13.2766 of the stake worth $3.24 million. The filing also reveals DEFENDER CAPITAL, LLC. as the second largest holder in the company with a control over 0.6682 of the outstanding shares. Its stake is worth $0.16 million for having 55220.0 shares in hand.
Currently, the stock has been recommended as Moderate Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.33 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Oncocyte Corporation has a debt to equity ratio of 0.41.
Technical Analysis of Oncocyte Corporation (NASDAQ:OCX) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Oncocyte Corporation (OCX), we notice that the stock’s 20-day average volume is at 61,620 shares and 50% of short term indicators are suggesting the stock as Sell. Its 50-day average volume of 38,722 shares. And to end, OCX’s 100-day average volume is 37,281 shares with 50% of the long-term indicators pointing towards Sell for the stock.
